KT-621 (STAT6) parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results